Minireviews
Copyright ©The Author(s) 2021.
World J Cardiol. Sep 26, 2021; 13(9): 464-471
Published online Sep 26, 2021. doi: 10.4330/wjc.v13.i9.464
Table 3 Summary of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure and the EMPEROR-Reduced trials
Ref.
Population (n)
Patients with T2DM
Intervention
Follow-up period (median)
Main results
DAPA-HF[22]HFrEF with or without T2DM (4744)42%Empagliflozin18 monthsCV death or HF (HR, 0.71; 95%CI, 0.65–0.85)
HF (HR, 0.70; 95%CI, 0.59–0.83)
CV death (HR, 0.82; 95%CI, 0.69–0.98)
EMPEROR-Reduced[9]HFrEF (3730)49.8%Empagliflozin16 monthsCV death or HF (HR, 0.75; 95%CI, 0.65–0.86)
HF (HR, 0.69; 95%CI, 0.59–0.81)
CV death (HR, 0.92; 95%CI, 0.75–1.12)